加味四妙勇安方对系统性红斑狼疮合并冠心病心绞痛患者脂代谢、炎症因子和血液流变学的影响

摘要 目的：观察加味四妙勇安方辅助治疗系统性红斑狼疮（SLE）合并冠心病心绞痛的疗效及对脂代谢、炎症因子和血液流变学的影响。方法：选取2019年5月~2022年3月期间我院收治入院的97例SLE合并冠心病心绞痛患者。按照随机数字表法将患者分为对照组（48例）和实验组（49例）。对照组接受常规西医治疗，实验组在对照组的基础上接受加味四妙勇安方辅助治疗。对比两组治疗后的疗效、脂代谢指标、炎症因子、血液流变学、心功能及临床症状改善情况。结果：实验组的临床总有效率高于对照组（P<0.05）。治疗后，实验组高密度脂蛋白胆固醇（HDL-C）高于对照组，低密度脂蛋白胆固醇（LDL-C）、总胆固醇（TC）、三酰甘油（TG）低于对照组（P<0.05）。治疗后，实验组超敏C反应蛋白（hs-CRP）、白介素-6（IL-6）低于对照组（P<0.05）。治疗后，实验组全血黏度（WBV）、纤维蛋白原（FIB）、血浆粘度（PV）、血小板黏附率（PAR）低于对照组（P<0.05）。治疗后，实验组左心室射血分数（LVEF）、心排血量（CO）高于对照组，心绞痛每次发作持续时间短于对照组，心绞痛发作次数少于对照组（P<0.05）。结论：加味四妙勇安方辅助治疗SLE合并冠心病心绞痛，可减轻患者的心绞痛症状，有效改善脂代谢、炎症因子和血液流变学。

Effect of Jiawei Simiao Yong'an Formula on Lipid Metabolism, Inflammatory Factors and Hemorheology in Patients with Systemic Lupus Erythematosus Complicated with Angina Pectoris of Coronary Heart Disease

ABSTRACT Objective: To observe the effect of Jiawei Simiao Yong''an formula on the adjuvant treatment of systemic lupus erythematosus (SLE) complicated with angina pectoris of coronary heart disease and its influence on lipid metabolism, inflammatory factors and hemorheology. Methods: 97 patients with SLE complicated with angina pectoris of coronary heart disease who were admitted to our hospital from May 2019 to March 2022 were selected. Patients were divided into the control group (48 cases) and the experimental group (49 cases) according to the random number table method. The control group received conventional Western medicine treatment, the experimental group received the auxiliary treatment of Jiawei Simiao Yong''an formula on the basis of the control group. The efficacy, lipid metabolism indexes, inflammatory factors, hemorheology, cardiac function and improvement of clinical symptoms in the two groups after treatment were compared. Results: The total effective rate in the experimental group was higher than that in the control group (P<0.05). After treatment, high density lipoprotein cholesterol (HDL-C) in the experimental group was higher than that in the control group, and low density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and triglyceride (TG) were lower than those in the control group (P<0.05). After treatment, the hypersensitive C-reactive protein (hs-CRP) and interleukin-6 (IL-6) in the experimental group were lower than those in the control group (P<0.05). After treatment, whole blood viscosity (WBV), fibrinogen (FIB), plasma viscosity (PV) and platelet adhesion rate (PAR) in the experimental group were lower than those in the control group (P<0.05). After treatment, the left ventricular ejection fraction (LVEF) and cardiac output (CO) in the experimental group were higher than those in the control group, the duration of each attack of angina pectoris was shorter than that in the control group, and the number of angina attacks was less than that in the control group (P<0.05). Conclusion: Jiawei Simiao Yong''an formula on the adjuvant treatment of SLE complicated with angina pectoris of coronary heart disease can reduce the symptoms of angina pectoris in patients, and effectively improve lipid metabolism, inflammatory factors and hemorheology.